ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.Scientific reports · 2019Pooled it
- The Prognostic Effect of Statin Use on Urologic Cancers: An Updated Meta-Analysis of 35 Observational Studies.Medicine · 2015Pooled it
- Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Cancer prevention research (Philadelphia, Pa.) · 2014 · on this mapPooled it
- Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Pooled it
- Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.The Prostate · 2022Trial
- Factors Associated with Potentially Inappropriate Prescribing in Patients with Prostate Cancer.Journal of clinical medicine · 2025Article
- The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Risk of cancer in patients with heart failure who use digoxin: a 10-year follow-up study and cell-based verification.Oncotarget · 2017Article
- Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.Neoplasia (New York, N.Y.) · 2017Article
- Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review.Oncology letters · 2017Article
- Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.Nature communications · 2016Article
- Statin use and mortality of patients with prostate cancer: a meta-analysis.OncoTargets and therapy · 2016Article
- Metformin and breast and gynecological cancer risk among women with diabetes.BMJ open diabetes research & care · 2015Article
- Metformin--mode of action and clinical implications for diabetes and cancer.Nature reviews. Endocrinology · 2014Review
- Trial watch: Cardiac glycosides and cancer therapy.Oncoimmunology · 2013Article
- Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells.PloS one · 2013Article
- Friend or foe? The current epidemiologic evidence on selenium and human cancer risk.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2013Review
- Metformin and the risk of cancer: time-related biases in observational studies.Diabetes care · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe TAX 327 trial was pivotal in establishing docetaxel in castration refractory metastatic prostate cancer. Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties and/or could potentially have pharmacokinectic interactions with docetaxel lessening the effectiveness of chemotherapy.
methodsTo examine the effect of on prostate cancer outcomes within this trial, we examined overall survival, prostate-specific antigen (PSA) response, percent PSA reduction, pain response and QOL responses for 14 families of medications including metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol, antidepressants and erythropoietin.
resultsOur findings did not reveal any medication that had a significant additive or synergistic effect with docetaxel. We did note, however, that patients on digoxin or verapamil had poorer overall survival, possibly due to a trend of fewer cycles of administered chemotherapy being administered to the verapamil group, consistent with a pharmacokinectic interaction.
conclusionsThese data are only hypothesis-generating given the statistical limitations, but may form a basis for similar future analysis in other malignancies. The data suggest the need to be aware of pharmacokinectic interactions with medications that may interact with docetaxel.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.